Pasithea Therapeutics Corp. (KTTA) stock
KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.51+0.08 (+17.64%)
Close on Nov 18, 2026Market cap $17.07MP/E –Yield –
Pasithea Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Pasithea Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$23.96M. For fiscal 2025 it was -$20.86M. The highest annual figure on record is -$4.51M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$20.86M | – |
| FY2024 | Dec 31, 2024 | -$14.25M | – |
| FY2023 | Dec 31, 2023 | -$15.98M | – |
| FY2022 | Dec 31, 2022 | -$12.59M | – |
| FY2021 | Dec 31, 2021 | -$4.51M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.71M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.88M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.26M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.81M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.26M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.95M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.04M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.15M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.79M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.21M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.86M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.61M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.08M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.27M | – |
| Q2 FY2021 | Jun 30, 2021 | -$727.95K | – |
| Q1 FY2021 | Mar 31, 2021 | -$549.61K | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.97K | – |
See a number that looks wrong?